People · Operator
Named in public records as an officer, director or promoter · active 2009–2016 · Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Symbiomix Therapeutics, LLC | — | Pharmaceuticals | Series B | $25.5M | $204.0M | 2013 |
| Zyngenia, Inc. | — | Other | Series A | $18.0M | $151.3M | 2009 |
Joseph Amprey at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joseph Amprey on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rishi Gupta | 1 | 12 |
| Ben Auspitz | 1 | 9 |
| Thomas Beck | 1 | 7 |
| Robert Garland | 1 | 7 |
| Klaus Veitinger | 1 | 6 |
| Peter Kiener | 1 | 4 |
| Peter A. Kiener | 1 | 3 |
| Robert Jacks | 1 | 2 |
| Robert F. Garland | 1 | 2 |
| Karen Dawes | 1 | 2 |
| Carlos F. Barbas, III | 1 | 1 |
| Joseph A. Amprey | 1 | 1 |
| Scott Mott | 1 | 1 |
| David F. Hilbert | 1 | 1 |
| Daniel A. Menichella | 1 | 1 |
| David F. Parkinson | 1 | 1 |
| Carlos Barbas | 1 | 1 |
| David F. Mott | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.